CPT 21030Surgery

Excise max/zygoma b9 tumor

CPT code 21030 covers the surgical removal of a non-cancerous (benign) tumor from the upper jaw bone (maxilla) or cheekbone (zygoma). This is a facial bone surgery typically performed to remove growths that may cause pain, deformity, or functional problems.

Showing rates for

National Average

Base Medicare rate

$449.29

This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.

RVU breakdown

Work RVU

4.91

PE RVU (NF)

8.48

MP RVU

0.5

Total RVU

13.89

Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High

NCCI bundling edits

Loading bundling edits…

Billing tips

Verify site of service coding (facility vs. non-facility) based on where procedure is actually performed, as this affects reimbursement by $92.83 per case
Impact: Incorrect place of service coding can result in $92.83 overpayment or underpayment, triggering audits or leaving money uncollected
Document tumor size in three dimensions (length x width x depth in centimeters) and exact anatomical location (which bone, which portion) to support medical necessity and defend against downcoding
Impact: Prevents denials for insufficient documentation which account for 15-20% of initial claim rejections for this code
Obtain pre-authorization with imaging studies (CT or MRI) showing bony involvement before surgery; many payers require prior authorization for facial bone procedures
Impact: Failure to obtain pre-auth can result in 100% claim denial ($449.29 loss) even when procedure is medically necessary
Bill separately for pathology interpretation if tumor is sent for histopathological evaluation; use appropriate 88000-series codes for surgical pathology
Impact: Recovers additional $50-150 in technical and professional pathology fees often overlooked when bundled incorrectly
When tumor extends into adjacent structures (orbit, sinus, nasal cavity), document clearly but consider whether a different, higher-value CPT code may be more appropriate
Impact: Using the correct code for complex resections can increase reimbursement by $200-500 compared to defaulting to 21030
Link to specific ICD-10 diagnosis codes for benign neoplasm of bone (D16.4 for maxilla, D16.5 for zygomatic) rather than generic mass codes

Live Field Datano reports yet

Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.

Working with CPT 21030?

Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.

Help build the field knowledge

MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.

Related actions

Frequently asked questions

What is the Medicare reimbursement rate for CPT 21030 in 2025?

Medicare pays $449.29 for CPT 21030 in non-facility settings and $356.46 in facility settings based on the 2025 Physician Fee Schedule. The code carries 13.89 total RVUs with a work RVU of 4.91.

What is the difference between CPT 21030 and soft tissue tumor excision codes?

CPT 21030 is specifically for tumors involving the maxillary or zygomatic bones themselves, requiring bone manipulation or removal. Soft tissue excision codes (21011-21016) are for tumors in the overlying tissues without bone involvement. The operative report must clearly document bone excision to justify 21030.

Can CPT 21030 be billed bilaterally with modifier 50?

Yes, when benign tumors are excised from both maxillae or both zygomas in the same operative session, modifier 50 is appropriate and typically increases reimbursement to 150% of the unilateral rate. Documentation must clearly support bilateral disease and bilateral surgical intervention.

Does CPT 21030 require prior authorization from insurance?

Most commercial payers and Medicare Advantage plans require prior authorization for CPT 21030 because it is a surgical procedure on facial bones. Traditional Medicare does not require prior authorization, but medical necessity must still be documented. Always verify specific payer requirements before scheduling.

What diagnosis codes are appropriate for billing CPT 21030?

Primary diagnosis codes include D16.4 (benign neoplasm of bones of skull and face - maxilla) and D16.5 (lower jaw bone). Other appropriate codes include M85.60 (other cyst of bone - unspecified site) with additional specificity, or K09.8 (other cysts of oral region) when appropriate to the tumor type.

Can CPT 21030 be billed with dental procedures on the same day?

Yes, but documentation must clearly separate the tumor excision from any dental services. Use modifier 59 or XS when appropriate. The tumor excision must address pathology beyond routine dental disease. Dental extractions related to tumor exposure are typically considered inclusive.

What is the global period for CPT 21030?

CPT 21030 has a 90-day global surgical period. All routine postoperative care within 90 days is included in the base reimbursement. Additional procedures during this period require modifiers 78 (related) or 79 (unrelated) to obtain appropriate payment.